Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic HCV Clear all
Completed Phase 1Phase 2 Interventional

A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

NCT01194037
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Genotype 1
Interventions
recombinant variant of interferon-alpha 2b, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Los Angeles, California • National City, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

NCT01741545
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Pegylated-Interferon-lambda, Ribavirin, Daclatasvir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Palo Alto, California • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

NCT00093093
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Viramidine, Ribavirin, pegylated interferon alfa-2a
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

NCT01808248
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection

NCT00565539
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
PEGylated recombinant interleukin 29 (PEG-rIL-29)
Drug
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Chicago, Illinois • Detroit, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2009 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

SMV + SOF With/Without RBV for IFN-II Patients With CHC

NCT02214420
View directory record Official record
Conditions
Hepatitis C
Interventions
Simeprevir, Sofosbuvir, Ribavirin
Drug
Lead sponsor
SC Liver Research Consortium, LLC
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
La Jolla, California • New York, New York • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

NCT00084279
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
Drug
Lead sponsor
InterMune
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Harvoni Treatment Porphyria Cutanea Tarda

NCT03118674
View directory record Official record
Conditions
Porphyria Cutanea Tarda, Hepatitis C
Interventions
Harvoni
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
San Francisco, California • Winston-Salem, North Carolina • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

NCT01331850
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, RO5024048, danoprevir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
La Jolla, California • Long Beach, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection

NCT02253550
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Peter J. Ruane, M.D.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00040027
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
46
States / cities
Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 20, 2026, 5:43 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082
View directory record Official record
Conditions
Hepatobiliary Diseases
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Not applicable Interventional

Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients

NCT03057236
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
Cognitive Behavior Coping Skills
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 4 Interventional Results available

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

NCT00087633
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], Copegus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

NCT01795911
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Lambda, Ribasphere, Daclatasvir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

NCT01938430
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

NCT01591668
View directory record Official record
Conditions
Hepatitis C
Interventions
Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01225380
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 20, 2026, 5:43 AM EDT
Not listed Phase 2 Interventional

Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

NCT01872936
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Miravirsen, Telaprevir, Ribavirin
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

NCT00215865
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
PEGIntron plus ribavirin
Drug
Lead sponsor
Hepatitis Resource Network
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2005 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

NCT01330316
View directory record Official record
Conditions
Hepatitis C
Interventions
BI 201335, PegIFN/RBV
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607735
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 20, 2026, 5:43 AM EDT
Withdrawn Phase 4 Interventional

Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1

NCT02485080
View directory record Official record
Conditions
PT-NANBH
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 72 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Palo Alto, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

NCT01170962
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-790052, Placebo, peginterferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
35
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 20, 2026, 5:43 AM EDT